

Eli Lilly vs Novo Nordisk
Major US pharmaceutical company leading diabetes and obesity treatments vs Global leader in diabetes and obesity treatments. Which is the better buy for your portfolio in November 2026? Plain-English answer below.
Eli Lilly has transformed into one of the most valuable pharmaceutical companies on earth, driven by its GLP-1 obesity and diabetes franchise that's reshaping how the industry thinks about blockbuster drugs, while Novo Nordisk invented the GLP-1 category and built a decades-long diabetes dominance before Lilly arrived to contest it. Both are racing to manufacture, distribute, and expand the clinical use of weight-loss treatments in a market that analysts describe as generational in size. Eli Lilly vs Novo Nordisk is the defining pharmaceutical rivalry of this decade, a head-to-head battle between two innovation machines competing for the same massive patient population.
Eli Lilly has transformed into one of the most valuable pharmaceutical companies on earth, driven by its GLP-1 obesity and diabetes franchise that's reshaping how the industry thinks about blockbuster...
Why It’s Moving

Lilly Rallies on Pipeline Wins, Acquisition News, and Record Highs
- Shares hit a record high after technical analysis indicated further upside potential, fueled by a $1.5 billion agreement to acquire Calytrix Bio for rare blood cancer therapies and a $3.5 billion investment in a new Pennsylvania manufacturing site.
- New clinical data presented at ObesityWeek showed retatrutide reduced sleep apnea severity and knee pain, while EloraTZP delivered substantial weight loss and A1C improvements, reinforcing Lilly's leadership in next-generation metabolic treatments.
- The company expanded patient access through a partnership with Hims & Hers to offer FDA-approved drugs like Zepbound and Foundayo, although a recent extortion threat involving vendor-held patient data briefly raised security concerns.

Novo Nordisk Shares Climb on Wegovy Pediatric Data and Hemophilia Approval
- European Commission approval of Frehemgo for Hemophilia A adds a new revenue stream to the portfolio, supporting the company's diversification strategy beyond metabolic diseases.
- New clinical results show Wegovy significantly lowered body mass index in children aged 6 to under 12, addressing a major unmet medical need where no other medications are currently approved.
- The stock rose premarket following these announcements, highlighting renewed confidence in Novo's ability to expand its addressable market despite ongoing pricing pressures and patent expiration concerns.

Lilly Rallies on Pipeline Wins, Acquisition News, and Record Highs
- Shares hit a record high after technical analysis indicated further upside potential, fueled by a $1.5 billion agreement to acquire Calytrix Bio for rare blood cancer therapies and a $3.5 billion investment in a new Pennsylvania manufacturing site.
- New clinical data presented at ObesityWeek showed retatrutide reduced sleep apnea severity and knee pain, while EloraTZP delivered substantial weight loss and A1C improvements, reinforcing Lilly's leadership in next-generation metabolic treatments.
- The company expanded patient access through a partnership with Hims & Hers to offer FDA-approved drugs like Zepbound and Foundayo, although a recent extortion threat involving vendor-held patient data briefly raised security concerns.

Novo Nordisk Shares Climb on Wegovy Pediatric Data and Hemophilia Approval
- European Commission approval of Frehemgo for Hemophilia A adds a new revenue stream to the portfolio, supporting the company's diversification strategy beyond metabolic diseases.
- New clinical results show Wegovy significantly lowered body mass index in children aged 6 to under 12, addressing a major unmet medical need where no other medications are currently approved.
- The stock rose premarket following these announcements, highlighting renewed confidence in Novo's ability to expand its addressable market despite ongoing pricing pressures and patent expiration concerns.
Investment Analysis

Eli Lilly
LLY
Pros
- Eli Lilly dominates GLP-1 market with superior U.S. momentum in Mounjaro and Zepbound sales.
- Advanced oral GLP-1 pipeline positions it ahead in next-generation obesity treatments.
- Stronger pricing power and revenue growth outpace Novo Nordisk amid competition.
Considerations
- Intensifying rivalry from Novo Nordisk's oral Wegovy launch erodes market share.
- Regulatory delays for oral candidates heighten execution risks in innovation race.
- Exposure to compounded semaglutide pressures margins and long-term profitability.

Novo Nordisk
NVO
Pros
- Launch of oral Wegovy provides first-to-market edge in convenient GLP-1 formulations.
- Semaglutide patent upheld in China bolsters global intellectual property protection.
- Recent U.S. rollout via Amazon Pharmacy expands Wegovy accessibility and demand.
Considerations
- Declining 2026 earnings estimates signal weakening profitability outlook.
- Intensifying GLP-1 competition from Eli Lilly hampers Ozempic and Wegovy growth.
- Pricing pressures and self-pay discounts raise concerns over margin compression.
Eli Lilly (LLY) Next Earnings Date
The next earnings date for LLY has not been confirmed yet. Based on the historical reporting pattern, where the company typically releases results approximately three months after the previous report, the expected timing is early February 2027. This upcoming release will cover the fourth quarter of fiscal year 2026.
Novo Nordisk (NVO) Next Earnings Date
No confirmed upcoming earnings date is currently listed for Novo Nordisk. Based on the historical reporting pattern, the next release is expected in early February 2027, approximately three months after the November 4, 2026 report. This upcoming announcement will cover the company's fourth quarter and full-year financial results for 2026.
Eli Lilly (LLY) Next Earnings Date
The next earnings date for LLY has not been confirmed yet. Based on the historical reporting pattern, where the company typically releases results approximately three months after the previous report, the expected timing is early February 2027. This upcoming release will cover the fourth quarter of fiscal year 2026.
Novo Nordisk (NVO) Next Earnings Date
No confirmed upcoming earnings date is currently listed for Novo Nordisk. Based on the historical reporting pattern, the next release is expected in early February 2027, approximately three months after the November 4, 2026 report. This upcoming announcement will cover the company's fourth quarter and full-year financial results for 2026.
Buy LLY or NVO in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.